
Loading, please wait...

Loading, please wait...

Recent research highlights herbal treatments for dementia as potentially valuable options for managing the symptoms of Alzheimer’s disease. Given the clinical challenges and side effects associated with standard medications, many physicians and researchers are exploring phytopharmaceuticals as complementary therapies. A comprehensive systematic review recently analyzed 48 human trials to evaluate the efficacy and safety of these botanical interventions.
The review identified significant cognitive improvements following the administration of Ginkgo biloba and Crocus sativus (Saffron). Furthermore, some herbal formulations demonstrated symptomatic efficacy comparable to donepezil, a gold-standard acetylcholinesterase inhibitor. These findings suggest that specific plant-based extracts could play a significant role in managing cognitive decline. For instance, the neuroprotective properties of these herbs may help mitigate oxidative stress and improve blood flow within the cerebral environment. However, researchers emphasize that while short-term symptomatic effects are promising, the evidence remains insufficient to claim superiority over conventional drugs.
Safety profiles for most reviewed phytopharmaceuticals appeared favorable compared to standard allopathic treatments. Consequently, these options are particularly relevant for patients who experience contraindications or poor tolerability with current medications. Nevertheless, many studies are limited by small sample sizes and brief intervention periods, often lasting only three to six months. This duration is too short to determine if these herbal treatments for dementia function as disease-modifying treatments (DMTs). Therefore, long-term research is essential to confirm whether these therapies can truly alter the underlying pathology of neurodegeneration.
Clinical trials indicate that certain extracts, such as Ginkgo biloba, may offer symptomatic benefits similar to donepezil in the short term. However, more robust data are required to prove they are equally effective for long-term management.
The systematic review highlighted Ginkgo biloba and Crocus sativus (Saffron) as the most effective herbal interventions for improving cognitive outcomes in dementia patients.
Current evidence suggests these treatments primarily offer symptomatic relief. There is no definitive data yet to classify them as disease-modifying treatments that can stop or reverse the progression of Alzheimer’s.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Kaczmarek-Kryszak KA et al. A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer's disease and dementia. Acta Neuropsychiatr. 2026 May 08. doi: 10.1017/neu.2026.10085. PMID: 42100836.
Georgetown University School of Medicine. Study Finds No Evidence of Benefit for Ginkgo Biloba in Cognitive Impairment; Possible Benefit in Dementia. Cochrane Database Syst Rev. 2026 Feb 05. doi: 10.1002/14651858.CD013661.pub2.
Hasanat A et al. Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review. MDPI. 2025 Feb 19. doi: 10.3390/pharmaceutics17020214.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review examines the efficacy of herbal treatments for dementia, suggesting Ginkgo biloba and Saffron may offer symptomatic benefits....
4 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today